The tobacco industry giant, Altria Group, has undergone a phase of volatile stock performance in recent years. While investors have celebrated periods of increase, the company's outlook remain a topic of contention. Factors influencing Altria Group's stock consist of regulatory changes, market preferences, and the general well-being of the tobacco

The FDA has issued a warning about the risks of smuggled tirzepatide as the peptide therapeutics market grows rapidly. The market is expected to jump from $38 billion in 2023 to $106 billion by 2033, with an impressive 10.8% compound annual growth rate. Legitimate peptide medications have revolutionized modern medicine, with 102 FDA-approved therap